Company Filing History:
Years Active: 2015-2017
Title: Innovations of Peter French in RNA Interference Technology
Introduction
Peter French is a notable inventor based in Balmain, Australia, recognized for his contributions to the field of RNA interference (RNAi) technology. With a total of four patents to his name, he has made significant strides in developing treatments for various medical conditions, including hepatitis B and chronic pain.
Latest Patents
One of Peter French's latest patents focuses on HBV treatment. This invention is directed to an RNA interference agent and its application in treating hepatitis B infection in individuals. The patent details pharmaceutical compositions that contain RNAi agents designed to inhibit the expression of at least one Hepatitis B virus gene. The RNAi agents comprise effector sequences that are complementary to a predicted sequence transcribed from a target region. In some instances, the agent includes multiple effector sequences that may target the same region of an HBV gene or different HBV genes.
Another significant patent by French relates to pain treatment. This disclosure involves an RNA interference agent aimed at treating chronic pain in individuals. The DNA-directed RNA interference agent is designed to inhibit the expression of one or more target sequences in pain-associated genes. It comprises effector sequences that are substantially complementary to the predicted transcript of a target sequence within these genes.
Career Highlights
Peter French is currently associated with Benitec Biopharma Limited, a company that focuses on developing innovative therapies based on RNAi technology. His work at Benitec has positioned him as a key player in the advancement of RNAi applications in medicine.
Collaborations
Peter collaborates with notable colleagues, including Michael Wayne Graham and York YuanYuan Zhu. Their combined expertise contributes to the innovative research and development efforts at Benitec Biopharma Limited.
Conclusion
Peter French's work in RNA interference technology has the potential to revolutionize treatments for hepatitis B and chronic pain. His innovative patents and collaborations highlight his significant contributions to the field of medical research.